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The Virtual Pathology Slide is an interactive microscope emulator that 
presents, via the Internet, a complete digitalised tissue section of size 
15.53mm x 11.61mm. VPS mimics the use of a microscope in both the 
stepwise increase of magnification (from 16x up to 2000x) and in lateral 
motion in the x and y Cartesian directions. This permits a pathologist to 
navigate to any area of a slide, at any magnification, similar to a conventional 
microscope. To learn more about the VPS access http://www. 
telepathology.dcu.ie. 
The system incorporates a novel ability to monitor, and time a pathologist￿s 
actions while examining a VPS slide. This monitoring, coupled with online 
feedback forms, allows the VPS to trace the complete decision making 
process of pathologists, engaged in the process of microscopic diagnosis. 
Unique features such as a bandwidth speed test permits the examination, in 
real time, of user satisfaction with respect to system performance. 
In order to assess, the diagnostic accuracy and acceptability of the VPS, ten 
wide bore breast needle core biopsies were randomly selected and presented 
to fifteen pathologists, with at least two years experience. The participants 
were required to examine each case online and provide a diagnostic 
classification using online feedback forms. The recorded data permitted 
examination of user satisfaction and inter-observer variability. Parameters 
measured include, time taken to complete an examination, time spent viewing 
a slide at a given magnification, and variability in the region of tissue 
examined by participants for each case. 
This study evaluated the performance of the VPS as a diagnostic tool and 
provided an insight into the decision making process of breast needle core 
biopsy classification. 
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SURGICAL OUTCOME OF WIRE LOCALISATION EXCISION OF 
MAMMOGRAPHIC LESIONS BY A PERI-AREOLAR APPROACH. 
J. Ramus, C. Meyer and S. Shrotria,   
Ashford and St. Peter￿s NHS trust, Middlesex, U.K 
Background:  Wire localisation excision is an important diagnostic and 
therapeutic procedure for women with benign and malignant impalpable 
breast lesions. The ratio of benign to malignant disease is increasing and 
cosmetic outcome is therefore becoming an even more important factor when 
planning surgery in these patients. In most practices in this country 
localisation excisions are done via an approach directly over the wire.
Methods:  We studied 43 patients who had  undergone wire localisation 
excisions of breast lesions between 1998 and 2001. All but 4 patients were 
operated on using a peri-areolar approach. Volumes of tissue excised, 
adequacy of resection for malignant disease, the need for further surgery, 
distance form the nipple to the lesion and subsequent cosmetic outcome were 
all examined.
Results: The average volume of tissue excised in patients with malignant 
disease was 142.24cm3; in patients with benign disease this was 94.35cm3. 7 
patients were found to have inadequate resection margins and went on to 
have mastectomies. 30 patients were assessed in a special follow up clinic of 
which 27 were 80% or more satisfied with their cosmetic result. The distance 
of the lesion from the nipple did not appear to compromise adequacy of 
resection nor cosmetic outcome. Patients with a cytological diagnosis of 
malignancy pre-operatively were found to have on average 50% more tissue 
excised than those without.
Conclusion: Wire localisation excisions for impalpable breast lesions done 
via a peri-aereolar  approach give good cosmetic results without 
compromising histological resection margins. 
P3 
THE VALUE OF 99mTc SESTAMIBI SCINTIMAMMOGRAPHY IN 
THE MANAGEMENT OF SUSPECTED LOCAL RECURRENCE IN 
PATIENTS WHO HAVE UNDERGONE BREAST CONSERVATION 
SURGERY
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Background : The detection of local recurrence after breast conservation 
treatment is often difficult and frequently necessitates biopsy.  99mTc 
sestamibi scintimammography (SSM) is a nuclear medicine technique which 
provides functional breast imaging.  This study was aimed to evaluate the 
role of SSM in the investigation and management of local recurrence.   
Patients and Methods :  Up to 130 patients were treated with breast 
conservation surgery annually in our breast unit. Between January 1999 and 
November 2001 during routine follow up 29 patients with clinical or 
mammographic suspicion of local recurrence were seen.  SSM scans were 
performed in all patients and where there was suspicion of recurrence MRI 
scans were also carried out. In those with suspicious MRI scans a biopsy was 
performed for histological confirmation.  Those with negative SSM result 
simply had long clinical follow up.  Mean follow up period was 14.5 months.   
Results : Twenty four patients had negative SSM scans.  In three patients 
where the clinical suspicion was high, excision biopsy was carried out.   
Histology was benign for all three patients.  The remaining twenty one 
patients with negative SSM scans had no evidence of clinical or radiological 
recurrence on long term follow up.  Five patients who had suspicious SSM 
scans also had suspicious MRI scans, which necessitated biopsies.  Histology 
was benign in all except one confirmed recurrence.  The specificities of SSM 
and MRI were 85.7% and 14.2% respectively. 
Conclusion : SSM is a useful tool in the management of patients with 
suspected local recurrence following breast conservation treatment.  We 
believe that SSM should be the first line investigation in equivocal cases of 
suspected local recurrence. If an SSM result is negative, biopsy may be 
avoided in most cases and a close long term follow up may suffice.  A 
suspicious SSM result, on the other hand is a strong indication for MRI.  
When both SSM and MRI are suspicious, we would recommend that 
histology is obtained.  
P4 
AN ANALYSIS OF BREAST CANCER PATIENTS￿ VIEWS ON 
ENTRY INTO SEVERAL CLINICAL STUDIES.
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Introduction:  Studies that have been conducted on the patient￿s experience 
of trial participation focus on such issues as informed consent, the shared 
decision making process and understanding trial design.  Patients who have 
been diagnosed with breast cancer are likely to be asked to join a number of 
clinical studies throughout their treatment.  Some research and ethics 
committees have expressed concerns about the number of research studies a 
patient may be asked to join.  The opinion of patients has not been sought to 
support these views.  The aim of this analysis was to ask the opinions of 
breast cancer patients about their experience of study participation. 
Patients and methods:  Ninety-six patients who had surgery for breast 
cancer Jan-June 2000, were sent a questionnaire on study participation.  The 
questionnaire consisted of nine questions with space for comments. The 
patients were assured their results would be anonymised.  
Results: Eighty-one out of 96 (84%) questionnaires were returned and 50 
(64%) were from patients who were asked to join a clinical research study.  
Almost two thirds of patients who were asked to join a research study   
(32/50) did not believe that participation in clinical studies should be 
restricted (group 1).  Of the remaining 18 patients (group 2) 13 stipulated the 
maximum number of studies that should be offered.  Two of these patients 
quoted unrealistically high figures of 100 or 500 studies offered per patient.  
These patients could be included in group 1, as this does not represent a 
meaningful limit to trial entry.  The amended figures for groups 1 and 2 are 
34/50 (68%) and 11/50 (22%).  Amongst the patients in group 2 who 
believed there should be a numerical limit on the number of studies offered, 
just over half, 7 (53%) considered 3 or fewer trials to be an acceptable 
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be.  Overall, 35/50 did not believe that involvement in more than one study 
was a significant burden.  43/50 (86%) of patients did not consider the 
demands of the study to be more than expected.  90% of patients felt that 
participation in studies was worthwhile and no patient regretted their decision 
to take part in a study. 
Conclusions:  The majority of patients believed there should not be a limit to 
the number of studies offered. This survey has further demonstrated that 
patients are keen to participate in research studies if they are given enough 
time to decide and a clear explanation in order to make an informed choice.  
The NHS Cancer Plan places patients￿ views as central to the delivery of 
good cancer care. Clinicians need to understand and respond to the concerns 
of patients who are going to increasingly be asked to enter clinical studies.  
This survey demonstrates that the majority of patients questioned were keen 
to participate in more than one clinical study, and only 3/50(16.6%) believed 
that the number of studies offered should be 3 or less.  On the other hand 
90% of patients felt that participation in studies was worthwhile and no
patient regretted her decision to take part in a clinical research study. 
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MODULATION OF CDC2 KINASE-SURVIVIN EXPRESSION IN 
BREAST CANCER APOPTOSIS
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Aims:-Mechanisms by which basic fibroblast growth factor (bFGF) interacts 
with COX inhibitors to dysregulate breast cancer cell apoptosis were 
investigated.  Methods and Results:- Stimulation of MCF-7 cancer cells with 
(bFGF) decreased apoptosis and induced up-regulation of the mitochondrial 
protein, Bcl-2 without altering the expression of Bax. COX inhibitors, 
meloxicam (selective COX II) and aspirin (non-selective) but not SC 560 
(selective COX I) induced cancer cell apoptosis as assessed by quantifying 
total intracellular nucleosomes and confirmed by TUNEL. Pre-treatment with 
meloxicam and aspirin modulated the anti-apoptotic effect of bFGF. bFGF 
stimulation rapidly increased survivin and phospho-cdc2 expression. COX 
inhibitors decreased basal expression of Bcl-2, survivin and prevented their 
up-regulation seen with bFGF pre-treatment. Phosphorylation of cdc2 by 
bFGF was reduced in the presence of meloxicam and aspirin. COX II 
expression however was low and not inducible by bFGF. PGE2 was unaltered 
in both control and bFGF groups. Conclusion:-These findings suggesting 
that COX inhibitors modulate breast cancer cell survival by interfering both 
cell cycle-independent (mitochondrial Bcl-2) and a cell cycle-dependent 
(cdc2 kinase-survivin) apoptosis pathways independent of COX II activities. 
The anti-survivin properties of aspirin and meloxicam in our in vitro model 
may explain the chemoprevention role of COX inhibitors. 
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IMMUNOHISTOCHEMICAL STUDY. 
N.Beechey-Newman *
1, H.Hamed
1, J.Skillman
1, C.d￿Ariggo
2, S.Clark
3,
I.S.Fentiman
1.
1.Breast Unit, Guy￿s Hospital, London SE1 9RT.UK 
2.ICRF Labs, Guys Hospital, London SE1 9RT. UK. 
3.Dept of Nuclear Medicine, Guys Hospital, London SE1 9RT. UK. 
Aims. To discover the true accuracy of sentinel node biopsy (SNB) by 
eliminating thev  bias that results from the more intensive histological 
assessment of the SN than non-SNs.   
Methods. Three hundred unselected (T1-3, N0-1), consecutive patients with 
primary  breast cancer had sentinel biopsy followed by level III axillary 
clearance. SN localisation  was by isotope (0.1ml nanocol, intra-dermal, 
lymphoscintigram) and dye (0.5 ￿ 1.0ml patent blue V, intra-dermal) in 112 
patients and dye only in 188 patients, the distribution being dependent on the 
availability of nuclear medicine facilities on the day of surgery and the 
consent of the patients. All sentinel and  non-sentinel nodes were treated 
identically by serial sectioning followed by H&E and immuno-histochmistry 
for cytokeratin (CAM 5.2). 
Results. A SN was identified in 250 (83.3%), 91.9% for isotope and dye 
compared to  dye alone, 78.2%, p=0.005). A mean of 1.4 SNs and 21.8 non-
SNs were retrieved. The  SN predicted the status of the rest of the axilla with 
an accuracy of 91.2% and a  sensitivity of 82.3%. There was no difference in 
the sensitivity of SNB between the  methods of localisation used (isotope and 
dye 84.6%, dye alone 81.1%). Statistical  analysis including logistic 
regression of 10 patient and methodological variants (age, tumour site, 
tumour size, histological type and grade, high node positivity, dye volume, 
previous excision biopsy, needle localisation and surgeon) demonstrated  that 
lobular histology (p=<0.05)and high node positivity (≥  4 positive nodes) 
(p=0.006) were independent  factors  associated with reduced SN 
identification. Needle localisation (p=0.062) and retroareolar tumour 
(p=0.058) site were close to being significant. None of the same 10 biological 
and methodological factors affected SNB accuracy. 
Conclusions. In this prospective study when patients are not selected and all 
of the  axillary nodes are cleared and treated by similar histological 
techniques the accuracy  and sensitivity of SNB is not as accurate as 
generally quoted. Different biological and methodological techniques affect 
the rate of identification of the SN but not its accuracy. 
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Aims. To assess the feasibility and technical factors that influence the 
successful visualisation of mammary duct epithelium using a purpose built 
breast micro-endoscope.   
Methods  We conducted ex-vivo duct micro-endoscopy on 35 mastectomy 
specimens.  Visualisation of mammary duct epithelium was achieved using a 
solid rod Depth of Field  Imaging (DOFI
R Mini) micro-endoscope consisting 
of a 0.89mm maximum outer diameter  rigid sheath, optical fibre and a 
working channel of 0.35mm. Insufflation was with air and  saline. 
Results  We could successfully visualise the duct epithelium in all 35 
specimens,  including in 2 specimens with inverted nipples. We examined  
104 ducts in all; an average of 3.3 (median 3) ducts per specimen. 
Visualisation of the proximal ducts (first 2 cm)  only was possible in 12/35 
(34%). Navigation beyond 2 cm was possible in 23/35 or 66%. In 18/104 
ducts we were able to navigate beyond a depth of 5 cm. The maximum  depth 
we were able to navigate to was 9.2 cm. In ducts with a pathological 
discharge distal navigation was achieved in 100% of the cases. Visualisation 
beyond three bifurcations of the ductal system was achieved in 32% of ducts. 
We could visualise pathological changes to duct epithelium in 8/35 patients 
who had DCIS or invasive malignancy. 
Conclusion  Breast duct micro-endoscopy is technically feasible. Besides 
having a role in patients with pathological nipple discharge, current 
techniques enable the examination of multiple normal calibre ducts. With 
improved instrumentation this procedure  could have use in the surveillance 
and diagnosis of breast cancer.
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Background. The treatment of Paget￿s disease by mastectomy has recently 
been challenged in favour of breast conserving techniques. A large series of 
patients treated with mastectomy has been reviewed to assess the feasibility 
of less radical surgery.   
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reviewed. The type, grade, receptor and node status, and the mammographic 
and pathological extent of the underlying breast malignancy were 
determined. The survival of patients with invasive disease was compared 
with matched controls without Paget￿s disease.  
Results. The underlying malignancy was invasive in 58%. Despite the fact 
that only one third presented with a palpable mass the malignancy was 
frequently extensive, being confined to the retro-areolar region in only 25%. 
The true extent of the disease was underestimated by mammography in 43% 
of cases. Of the patients with DCIS 96.5% were high grade and 100% of the 
invasive cancers were also of high cyto-nuclear grade. Over-expression of the 
c-erb-B2 oncogene was detectable in 83%. Patients with Paget￿s disease had 
a significantly worse survival than matched controls, but this difference was 
eliminated if they were also matched for c-erb-B2 status.  
Conclusions. Paget￿s disease is often associated with extensive underlying 
malignancy which is difficult to accurately assess either clinically or 
mammographically. As a consequence cone excision of the nipple would 
have resulted in incomplete excision in 75% of cases. In Paget￿s disease the 
underlying malignancy is of high grade and is frequently c-erb-B2 positive 
with a resulting poor prognosis. Aggressive local and systemic treatment 
therefore would seem to be merited.  
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INTERACTIONS BETWEEN ALPHA-1-ACID GLYCOPROTEIN 
AND TAMOXIFEN AND ITS METABOLITES MAY AFFECT DRUG 
EFFICACY 
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BACKGROUND: Several plasma proteins, of which alpha-1-acid 
glycoprotein (AGP) is one, are known to reversibly bind to drugs.  If a drug is 
bound to plasma components such as albumin or AGP, it may not be 
pharmacologically active, due to alterations in distribution and clearance, and 
this is of consideration in the design of drug dosage schedules.  In addition, 
the concentration of AGP has been shown to increase two- to five-fold (a 
process termed the acute phase response) in disease states, such as cancer, 
resulting in potentially higher binding of drug to AGP.  Thus, the binding of 
tamoxifen, a commonly used drug in the treatment of breast cancer, to AGP 
was investigated.  METHODS: The technique employed was a fluorescence 
quenching method, which has the benefits of being quick, sensitive and 
accurate.  It can be performed in a cuvette, or a 96-well microtitre plate if the 
quantity of drug or protein is small.  The method is based on the fluorescence 
of tryptophan residues, present in the AGP molecule, at 280nm excitation.  
Upon binding of the drug to AGP, the level of fluorescence is decreased, 
whereas if no binding occurs, there is no decrease in fluorescence.  The drugs 
investigated were tamoxifen citrate, tamoxifen free base and the 
physiologically active metabolite 4-hydroxytamoxifen.  RESULTS: When 
the fluorescence of 0.83mg/ml AGP at 300-400nm emission was recorded, a 
decrease in peak fluorescence at 335nm of 34% was noted after addition of 
1µ M tamoxifen free base to the AGP solution, indicating that the drug was 
partially bound to AGP.  Addition of 5µ M and 10µ M tamoxifen free base 
resulted in decreases in fluorescence of 87% and 96% respectively, which 
suggests that very little unbound drug would remain in the plasma.  At 
concentrations above 10µ M, quenching was greater than 98%.  Tamoxifen 
citrate was found to bind AGP to a lesser extent than that of the free base, 
with decreases in fluorescence of 23%, 72% and 91% following the addition 
of 1µ M, 5µ M and 10µ M drug, respectively.  Quenching of 99% was 
observed after addition of 50µ M tamoxifen citrate, suggesting almost 
complete binding of drug to AGP at this concentration.  The presence of 4-
hydroxytamoxifen, at 25µ M, resulted in a decrease in fluorescence of 55% 
compared to AGP solution alone.  This was much lower than the binding 
observed for either tamoxifen free base or tamoxifen citrate.  In stark contrast 
to tamoxifen free base, 96% decrease in fluorescence was found for 4-
hydroxytamoxifen at 250µ M, while the same fluorescence decrease was seen 
with only 10µ M tamoxifen free base.  CONCLUSION: In summary, the 
results indicated that tamoxifen free base binds to AGP slightly more than 
does tamoxifen citrate, however 4-hydroxytamoxifen is bound much less by 
AGP.  Since tamoxifen must be metabolised by the body to 4-
hydroxytamoxifen, binding of the pro-drug to AGP may hamper metabolism, 
hence it may take longer to achieve pharmacologically therapeutic levels of 
4-hydroxytamoxifen in vivo, thus possibly reducing the efficacy of the drug. 
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The estrogen receptors, ER-α  and ER-β , function as transcription factors to 
modulate expression of target genes.  ER-α   interacts with ￿coregulators￿ to 
enhance or inhibit transcription.  We hypothesised that these coregulators 
contribute to the differing clinical response of patients to treatment with 
tamoxifen. The aim of this project was to localise ER-α  and ER−β , the 
coregulator SRC-1 and the corepressor SMRT within breast tissue and to 
examine the ability of tamoxifen and β -estradiol to regulate the expression of 
ER-α  and SRC-1. 
ER-α , ER−β,  SRC-1 and SMRT were localised within paraffin embedded 
human breast tissue (n=11) by immunohistochemistry. Strong positive 
staining for ER-α ( 10/11) and ER-β ( 2/11) was detected in the nuclei of 
invasive ductal carcinoma and invasive lobular carcinoma. SRC-1 (2/11)  and 
SMRT (1/11) were found to be expressed to a lesser extent and were 
localised to nuclei of tumour cells. The ability of four hydroxytamoxifen (4-
HOT) and β -estradiol to regulate the protein expression of ER-α  and SRC-1 
in the breast tumour cell line MCF-7 was determined using Western Blotting. 
ER-α  was expressed within the cytoplasm and to a greater extent the nucleus 
of MCF-7 cells. Both 4-HOT and β -estradiol induced an upregulation of 
nuclear ER-α . ER-α  translocated from the cytoplasm to the nucleus in the 
presence of β -estradiol. SRC-1 was located within the nuclear fraction of 
MCF-7 cells and was up regulated in the presence of β -estradiol. 
Localisation of the coregulator SRC-1 within human breast tissue and the 
regulation of SRC-1 by β -estradiol in the breast tumour cell line MCF-7 is 
new evidence that coregulators modulate ER activation by β -estradiol and 
tamoxifen.  
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DIETARY PHYTOESTROGENS INHIBIT STEROID METABOLISM 
AND MAY INFLUENCE THE EXPOSURE OF BREAST CANCER  
CELLS TO ENDOGENOUS ESTROGENS. 
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Environmental estrogens are a diverse group of compounds that can exert 
estrogenic effects in living organisms. They include the ￿phytoestrogens￿, 
such as genistein and daidzein, which are natural constituents of soy-rich 
diets and which have been suggested to confer a reduced risk of developing 
breast cancer.  
Although some effects of environmental estrogens may be mediated by 
estrogen receptors, there is growing evidence that these compounds can 
influence endocrine balance by acting as substrates or inhibitors of key 
steroid-metabolising enzymes. We have investigated the influence of dietary 
phytoestrogens upon the activities of sulphotransferase and sulphatase 
enzymes active against estrogens in human platelet preparations. These are 
SULT1A1, the enzyme thought to be responsible for sulphating estrogens in 
MCF7 cells and in human breast tumours, and steroid sulphatase.  
Genistein, daidzein and other, less abundant dietary phytoestrogens were 
found to be inhibitors of both enzymes in human platelet preparations. (see 
table). 
Phytoestrogen IC50 against: 
 Steroid  sulphatase  vs. 
1µ M estrone sulphate 
SULT1A1 
vs. estradiol (10nM) 
Genistein  >25µ M       0.8µ M
Daidzein  >50µ M       1.0µ M
Quercetin n.d.       0.5µ M
Luteolin  >25µ M       0.4µ M
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phytoestrogens than is steroid sulphatase. In the presence of circulating 
concentrations of genistein and daidzein reported to exist in individuals 
consuming a high soy diet (~1µ M), SULT1A1 activity would be significantly 
inhibited whilst that of steroid sulphatase would be unaffected. This 
combination of effects upon the balance of estrogen sulphation/de-sulphation 
within breast tissue might be predicted to increase exposure to active (de-
sulphated) estrogens. However, in postmenopausal women, a significant pool 
of potentially active estrogen circulates as estrone sulphate synthesised from 
adrenal-derived DHEA, via the action of sulphotransferases and other steroid 
metabolising enzymes. Hence inhibition of sulphotransferase activity by 
phytoestrogens in postmenopausal women may reduce this pool of circulating 
estrone sulphate thereby reducing the exposure of tissues to active estrogens.  
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AIM: To assess the impact of mutations in the p53 gene on clinical response 
of breast carcinomas to chemotherapy. METHOD: Patients undergoing 
primary (neo-adjuvant) chemotherapy for breast cancer between April 1994 
and October 1998 were asked to participate in a fine needle aspiration (FNA) 
study of breast tumours.  FNAs were taken prior to treatment using a 23G 
needle and cytospins were prepared and air-dried before storage at -80
oC.
DNA was extracted from the cells using the Puregene Kit (Flowgen Ltd, UK) 
according to their standard protocol. Frozen MCF-7 cells were processed in 
parallel as controls. The p53 gene (exons 5-8) was amplified using a nested 
PCR regime, and sequenced manually. All mutations were confirmed on the 
opposite strand by further sequencing. The effect of a mutation on clinical 
response to chemotherapy was tested for significance using the Mann 
Whitney test with trend. Survival & progression free survival were 
determined by the life-table method of Kaplan & Meier and comparisons 
were made by means of the logrank test. RESULTS: Forty-six of 53 
available samples examined were successfully analysed. A total of 14 
alterations in 13 tumours (30%) were found in exons 5 ￿ 8 of the p53 gene, 
11 predicted functional modification of the protein. Of the mutations found, 
there were 7 base substitutions (51%), 1 deletion (7%), 2 silent mutations 
(14%), 2 mutations affecting gene splicing (14%) and 2 non-sense mutations 
(14%). Six mutations (43%) were present in, or disrupted the L2 and/or the 
L3 region of the gene, which are  
involved in DNA binding. Thirty-six patients out of 44 (82%) assessable for 
response to chemotherapy had a clinical response (6 no change, 2 progressive 
disease). Two patients could not be evaluated; both patients were found to 
have WTp53. No association was found between presence of p53 mutation 
(including L2/L3 region mutations only) and response to chemotherapy. 
Median relapse free survival (RFS) at 3 years was 74% overall, but was 64% 
for those with a mutation and 78% for those without (n.s). When the 
mutational data was spilt into two groups according to whether the mutation 
was in the L2/3 regions, RFS at 3 years was 50% for those with a L2/3 
affected mutation and 80% for those with mutations in other areas of p53 
(n.s).CONCLUSIONS: This analysis confirms the use of this method of 
DNA sequencing in FNAs as suitable for breast cancers. The incidence of 
mutation is consistent with that in other publications. Mutational states did 
not predict response, but showed a trend to an association with RFS. 
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Leptomeningeal carcinomatosis (LC) is a common manifestation of 
metastatic disease in solid tumours, occurring in 4-15% of patients. Breast 
cancer is the primary tumour most commonly associated with this condition. 
We have conducted a retrospective audit of the management of LC from 
breast cancer, in the Professorial Medical Oncology Unit in Leeds, during the 
period from January 1994 to March 2001. 
17 patients diagnosed as having LC secondary to breast cancer were 
identified during this period, 15 of whom have subsequently died. The 
incidence of LC was 5.8%. The mean age at diagnosis was 52 (range 35-70 
years).  
The women usually presented with multiple neurological symptoms, 
including headache, cranial nerve palsies, fitting and vomiting. 14 (82%) 
underwent investigation with lumbar puncture (LP), 11 (65%) had CT, 7 
(41%) had MRI and 2 (12%) had EEG. Only 50% of LPs yielded 
cytologically malignant cells, although an additional 41% showed other 
abnormalities such as atypical cells or raised protein. CT scan produced a 
diagnostic or suspicious result in only 36%, while MRI was diagnostic or 
suspicious in 85% of the patients. Diagnosis was made on a combination of 
clinical assessment, CSF analysis and radiological imaging. Thirteen of the 
women (77%) had 2 or more additional sites of metastatic disease, while in 2 
women (12%) LC was the only site of metastasis. 
Of the 17 women, 4 received no treatment either because they refused or 
were considered too unwell. 12 patients received intrathecal (IT) 
chemotherapy. 1 received radiotherapy alone, while 2 patients received 
radiotherapy as part of multi-modality therapy. 7 of the patients who were 
given IT treatment also received systemic chemotherapy. Response to 
treatment was determined by clinical improvement, disappearance of 
malignant cells from the CSF or resolution of leptomeningeal changes on 
MRI. 5 of the 12 patients (42%) receiving treatment including IT 
chemotherapy showed evidence of response to treatment. 
The median survival following diagnosis of LC was 17 weeks for all 17 
patients with LC, and 20 weeks for the 12 patients who received treatment 
including IT chemotherapy. However there were some longer term survivors: 
2 patients survived for 3 years 10 months and 2 years 1 month, while a 
further 2 patients remain alive at 14 months and 6 months. 
Data from this audit & a review of the literature has been used to compile 
proposed guidelines for the management of LC within the Yorkshire Cancer 
Network. 
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MAMMAGLOBIN A: A BREAST SPECIFIC MARKER. 
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Mammaglobin A (MGA) is a recently identified gene which appears to be 
expressed specifically in breast tissue. MGA is thus a potential marker for 
breast cancer. In this investigation, expression of MGA and mammaglobin B 
(MGB) were measured at the mRNA level by RT-PCR in 142 invasive breast 
carcinomas, 32 fibroadenomas and 21 specimens of normal breast tissue. 
MGA was detected in 86/142 (61%) of the breast cancers. In the cancers, 
expression was found more frequently in estrogen receptor-positive than 
estrogen receptor-negative samples (p< 0.01). Expression however, showed 
no significant relationship with either tumor size, axillary node status or 
progesterone receptor status. mRNA for MGB was present in 78/142 (55%) 
of breast cancers. MGB was found more frequently in cancers positive for 
MGA than in samples negative for this mRNA (p < 0.001). Overall, 73% of 
the cancers expressed either MGA or MGB. MGA was detected in only 1/23 
normal non-breast tissues and in none of 10 non-breast cancers. MGB was 
present in 4/14 non-breast normal tissues and in 1/8 non-breast malignancies. 
We conclude that expression of MGA is almost specific for breast tissue. 
MGA may therefore become the first relatively breast-specific marker. MGB, 
on the other hand, is less breast-specific but its presence may complement 
MGA in the detection of breast cancer. 
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A PHASE II TRIAL USING ETANERCEPT, A RECOMBINANT 
TUMOUR NECROSIS FACTOR ANTAGONIST, IN METASTATIC 
BREAST CANCER 
Forster M. D.∗ , Braybrooke J., Madhusudan S., Kaur K., Hoare S.° , Balkwill 
F.° , Ganesan T. S., Talbot D., Harris A. L. 
Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford 
OX3 7LJ, U.K., 
° Cancer Research UK Translational Oncology Laboratory, St. 
Bartholomew￿s Hospital, London, EC1M 6BQ, U.K. 
Purpose: There is preclinical data to support the role of TNF in the 
pathogenesis of breast cancer.  This activity is partially via angiogenesis and 
is mediated through activating secondary cytokines including MCP-1 and IL-
6.  Preclinical studies have shown Etanercept to effectively decrease the 
biological activity of TNF.  This phase II trial analysed the antitumour and 
biological effects of Etanercept in patients with metastatic breast cancer.  
Methods: Etanercept was given at a dose of 25mg SC twice weekly. The 
treatment was planned for a minimum of 3 months and a maximum of 1 year 
with objective re-evaluation every 3 months.  Surrogate markers used to 
measure the biological effects of TNF were plasma MCP-1 and a novel 
whole blood cytokine release assay of IL-6 and MCP-1.  These were 
measured pre-treatment, at 24 hours, 7 days, 28 days and 4 weekly there 
after.  
Results: 12 female patients with ductal or lobular breast cancer enrolled had a 
median age of 54 (34-74 yrs) and performance status ≤  2.  All patients had 
metastatic disease and had had multiple previous lines of therapy.  There 
were no significant toxicities.  All patients progressed despite therapy, with 
4/12 receiving at least 3 months treatment.  Plasma MCP-1 was essentially 
unchanged with a mean rise of 296pg/ml to 454pg/ml.  There was a gradual 
decrease in the MCP-1 release assay which was most pronounced at day 84 
(46% of pre-treatment values).  There was also a decrease in the IL-6 release 
assay at day 1 which was sustained at day 84 (27% of pre-treatment values). 
Conclusions: Etanercept has biological effects in patients with breast cancer, 
which are being evaluated further.  The trial is ongoing with a dose increase 
to 25mgs thrice weekly.  Further studies are warranted in combination with 
other antiangiogenic agents that inhibit different pathways.
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CELL LINE SPECIFIC RESPONSE OF THE P53 PATHWAY TO 
TAMOXIFEN IN BREAST CANCER
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Background: The anti-oestrogen tamoxifen remains the first-line endocrine 
treatment of choice for women with tumours positive for oestrogen receptors. 
Tamoxifen￿s anti-oestrogenic activity is in part attributed to its high affinity 
for binding to oestrogen receptors with subsequent alteration in the 
transcriptional activity normally attributed to the oestrodiol-bound oestrogen 
receptor complex. However not all patients with receptor positive tumours 
respond to the primary tamoxifen treatment. The exact mechanism by which 
tamoxifen inhibits tumour growth or, molecular changes that lead to 
tamoxifen resistance are not known. 
Aims: To examine the relation of the anti-tumour properties of tamoxifen 
with p53 and the p53-transactivated target gene p21 in breast cancer cell lines 
which differ in their p53 and oestrogen receptor status.  
Methods: Protein and mRNA expressions in response to tamoxifen treatment 
were determined by western and northern blot analyses respectively using 
highly sensitive human specific p53 monoclonal antibodies in ER
+/ p53
active,
ER
+/p53
mutant, ER
-/p53
mutant, ER
+/p53
dominant negative breast cancer cell lines.  
Results: In response to tamoxifen treatment a transient induction of p21 at 
the protein level in the absence of p53 protein induction was observed in 
MCF-7 oestrogen receptor positive, wild-type (active) p53, tamoxifen 
sensitive breast cancer cell lines. However p53 protein in tamoxifen treated 
cells was not phosphorylated at Ser392, a site whose modification is a 
sensitive probe for p53 activation in the absence of changes in p53 protein 
levels. This phenomenon was not observed in any of the other cell lines.  
Conclusion: These data suggest that p21 protein induction may be 
independent of p53 protein activation in ER
+/ p53
active breast cancer 
highlighting an alternative pathway for tamoxifen action. 
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CD55 AND CD59 AS INDEPENDENT INDICATOR OF POOR 
PROGNOSIS IN  BREAST CANCER PATIENTS 
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A better understanding of the molecular recognition and stimulation of 
immune responses has led to the development of many new approaches for 
the immunotherapy of cancer. CD59 (protectin) and CD55 (DAF) are 
membrane-associated complement regulatory proteins which inhibit 
complement￿mediated lysis of autologous cells. CD59, a phosphatidyl-
inositol-anchored glycoprotein, inhibits the formation of terminal membrane 
attack complex (MAC) of complement and is a second ligand for CD2 
contributing to T-cell activation. CD55, otherwise known as DAF (decay 
accelerating factor), is a GPI-anchored protein composed of 4 contiguous 
short consensus repeat (SCR) domains and a Serin/Threonine (S/T) rich 
region proximal to the cell surface which inhibits the complement cascade by 
inactivating C3 convertases and preventing C3b deposition on cell 
membranes. These complement proteins have been shown to be over-
expressed by a range of solid tumours and have been implicated in the limited 
success of antibody-mediated lysis of tumours. The levels of expression of 
these complement regulatory proteins may correlated with breast cancer 
progression and will aid in the design of new cancer vaccines. Over-
expression of CD55 has been shown to be an independent indicator of poor 
prognosis in colorectal cancer patients.  
Aim: The aim of present study is to determine whether expression of these 
antigens on breast tumours is associated with patient prognosis. There are 
multiple prognostic factors in breast cancer including size, lymph node, stage, 
differentiation and proliferation. The NPI is an integrated prognostic index 
based on tumour size, LN stage, and tumour grade, which used to predict 
patient survival for women with invasive breast cancer.  
Material and method: In this study the reactivity of anti- CD55 (clone 67) 
and anti-CD59 (MEM-43) on 300 and 600 breast carcinomas has been 
investigated by immunohistochemical staining using tissue microarrays. The 
level of expression of these antigens on breast tumours and tumour prognosis 
(grade, stage, size, oestrogen receptor, and NPI) has been evaluated.  
Results: Most breast carcinomas express CD55 weakly, however, CD59 was 
strongly expressed on 20% of breast tumours. Good prognosis patients 
(NPI1) had lower expression of CD55, whereas poor prognosis patients 
(NPI3) expressed higher levels of CD55 (P=0.016). CD59 expression was 
correlated with the grade of differentiation i.e., higher expression of CD59 
was more often found in well ￿and moderately differentiated tumours and 
lower levels of CD59 was found in poorly differentiated (P<0.001). 
Significant correlation was found between the percentages of cells stained for 
CD59 and survival (P<0.005). In contrast, no correlation was found between 
the percentage of cells expressing CD59 and multiple prognostic factors apart 
from tumour grade, indicating this may be an independent prognostic 
indicator for breast carcinomas.  
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INTRAOPERATIVE DETECTION OF METASTATIC AXILLARY 
NODES IN EARLY BREAST CANCER
Salem AA*, Douglas-Jones AG and Mansel RE, University of Wales College 
of Medicine, Cardiff,  
Background: Sentinel Node Biopsy (SNB) proved to be a reliable predictor 
of the axillary node status, which could help in operating on node-positive 
patients only. However, in order to avoid a second operation, a fast and 
reliable method for the intraoperative evaluation of the sentinel node(s) is 
needed.  
Aim: is to develop a fast and reliable method for the pathological evaluation 
of the sentinel nodes intraoperatively.   
Methods: We developed a protocol for rapid Immunohistochemistry (IHC) 
staining of touch imprints from axillary nodes intraoperatively and tested it 
on 349 nodes from 32 patients with early breast carcinoma who underwent 
Axillary Node Clearance (ANC) or SNB, and compared the results with those 
of permanent Haematoxylin and Eosin (H&E) sections. IHC-stained paraffin 
sections were done whenever the results of IHC-stained imprints were 
different from those of the H&E sections.  
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9 patients were positive on H&E. Two nodes were positive on IHC imprints 
and negative on H&E sections and that was confirmed on IHC sections. One 
of these two nodes was the only sentinel node in one patient. Only one of two 
positive nodes in an ANC was missed by IHC during the learning curve. On a 
patient basis, sensitivity was 100% and 90%, and Negative Predictive Value 
(NPV) was 100% and 96% for IHC and H&E respectively. On a node basis, 
sensitivity was 97% and 93%, and NPV was 99.6% and 99.3% for IHC and 
H&E respectively. Because of the absence of false positives, specificity and 
Positive Predictive Value (PPV) were 100% for both IHC and H&E.  
Conclusion: IHC-stained touch imprints could provide a sensitive and fast 
method for the intraoperative evaluation of axillary lymph nodes in breast 
cancer patients.  
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NEO-ADJUVANT CHEMOTHERAPY HAS NO EFFECT ON MAPK 
AND p38 ACTIVATION IN BREAST CANCER PATIENTS 
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Introduction Mitogen-activated protein kinases (MAPK) and p38 are 
involved in coordinating cellular responses to stress, with alterations in these 
pathways being involved in cancer pathogenesis. There is evidence of 
constitutive MAPK activation and expression in human breast cancer tissues. 
p38 activity in human tissues is not well documented. The aim of this study 
was to examine MAPK and p38 activity in human breast cancer tissues 
treated with combination chemotherapy containing doxorubicin and compare 
this with cancers not exposed to chemotherapy.  
Materials and Methods Human breast cancer tissues (0.5 cm
3) were 
obtained at mastectomy in compliance with MRC guidelines from 18 patients 
who underwent neo-adjuvant chemotherapy and 14 previously untreated 
patients. Following tissue lysis, supernatants were recovered to determine 
kinase activity. MAPK and p38 activity was determined by kinase assay for 
the appropriate substrate and western blot analysis. MAPK and p38 activities 
in the neo-adjuvant and untreated groups were correlated with the 
Nottingham Prognostic Index (NPI). As doxorubicin is known to act on the 
mechanisms involved in the multidrug resistance phenomenon, Pgp 
expression in 10 neo-adjuvantly treated tissues was also determined via 
immunoblotting and immunohistochemistry. 
Results MAPK and p38 activity could be shown in both groups of patients. 
Similar patterns of MAPK and p38 activity were seen in individual patients, 
but were unrelated to whether the patient had previous neo-adjuvant 
chemotherapy. No correlation was observed between either kinase activities 
and the NPI. Pgp expression was not demonstrated in 5 of the neo-adjuvantly 
treated cancers. 
Conclusion  The similar patterns found for each patient with respect to 
MAPK and p38 activity suggests their interaction within a given tumour 
rather than any association with the use of doxorubcin. Furthermore, the lack 
of correlation found between alterations in kinase activity, known to play a 
role in drug resistance, and Pgp expression, could suggest the importance of 
timing between drug exposure and mastectomy, where early mastectomy 
following neo-adjuvant treatment might prevent Pgp expression and therefore 
drug resistance.  
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BLACK WOMEN WITH BREAST CANCER ARE MORE LIKELY 
TO BE ER-BETA POSITIVE
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Introduction: A recent study has demonstrated that almost half of unselected 
estrogen receptor alpha (ER-a) negative patients are estrogen receptor beta 
(ER-b) positive, and that these patients may benefit from adjuvant hormonal 
therapy
1. African-American (AA) or Black patients are less likely to be ER-a 
positive and ER-b status is unknown.  
Purpose: To evaluate and compare ER-b expression in unselected AA and 
non-AA patients, and determine relationships with ER-a, progesterone 
receptor (PR), and HER-2/neu (Her2) expression.  
Methods: Immunohistochemical study using anti-ER-b antibodies (Affinity 
BioReagents). More than 10% staining was considered positive for ER-b. 
ER-a, PR and Her2 were determined by routine immunohistochemistry.  
Results: 24 patients were studied with a mean age of 55 years old (range 34 
to 71). There were 15 AA and 9 non-AA (predominantly white) patients. For 
the entire group, results were as follows; 38% ER-a positive (>5% staining), 
33% PR positive (>5% staining), 38% Her2 positive (2 or 3+ staining) and 
67% ER-b positive. 44% of ER-a positive and 80% of ER-a negative patients 
were ER-b positive; 38% of PR positive and 81% of PR negative patients 
were ER-b positive; 56% of Her2 positive and 73% of Her2 negative patients 
were ER-b positive. For AA patients results were; 33% ER-a positive, 27% 
PR positive, 27% Her2 positive and 73% ER-b positive. 60% ER-a positive 
and 80% ER-a negative patients were ER-b positive. 82% PR negative and 
91% Her2 negative patients were ER-b positive. For non-AA patients, results 
were; 44% ER-a positive, 44% PR positive, 55% Her2 positive and 55% ER-
b positive. 50% ER-a positive and 60% ER-a negative patients were ER-b 
positive. 25% PR negative and 50% Her2 negative patients were ER-b 
positive.  
Conclusions: Levels of expression of ER-b were higher for AA or Black 
patients. For both AA and non-AA patients, ER-b expression was higher 
when ER-a status was negative. Black ER-a negative, PR negative and Her2 
negative patients were most commonly ER-b positive. 
1. Mann  S.  et al. Human Pathology 2001: Volume 32: 113-118. 
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HER-2/NEU OVEREXPRESSION IN BLACK WOMEN WITH 
BREAST CANCER IS NOT ASSOCIATED WITH NEGATIVE ER 
STATUS OR HIGHER STAGE DISEASE
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Introduction: HER-2/neu (Her2) overexpression in breast cancer is 
associated with worse prognosis, estrogen receptor (ER) negative tumors and 
more aggressive disease. African-American (AA) or Black women have 
poorer prognosis, are more often found to have ER negative tumors and 
present with higher stage disease
1.
Purpose: To compare Her2 overexpression in AA and non-AA patients and 
determine whether such expression is related to negative ER status, node 
positive status and higher disease stage at presentation.  
Methods: 158 consecutive cases (106 AA and 52 non-AA) with breast 
cancer were evaluated for ER and Her2 expression with 
immunohistochemistry, and analyzed by race, stage (AJCC I vs. II-IV), and 
ER & node status.  
Results: There were no significant differences between groups and 58% AA 
and 54% non-AA (predominantly white) patients were ER positive (> 5% 
staining). Only 28% AA and 29% non-AA of ER positive patients were Her2 
positive (2 or 3+ staining). For ER negative patients, non-AA was almost 
twice as likely to be Her2 positive (54%), compared with AA (30%) (Chi-
square p=0.05). Non-AA Her2 positive patients were more likely to have 
higher stage (II-IV) disease (46 vs. 30%). All (100%) non-AA Her2 positive 
ER negative patients were higher stage, in contrast to 64% of similar AA 
patients. The majority (64%) of AA Her2 positive ER negative patients were 
node negative. In contrast, most (67%) non-AA Her2 positive ER negative 
patients were node positive.  
Conclusions: Her2 expression appeared to be similar for AA or Black 
patients, whether ER positive or negative, and was generally lower than 
expression for Non-AA patients. Her2 expression in AA patients was not 
associated with negative ER status, node positive status, or higher stage 
disease. 
1.  Joslyn S.A. & West M.M. Cancer 2000: Volume 88: 114-23.  
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A CHECKLIST FOR PATIENTS ON ENDOCRINE THERAPY (C-
PET): RESULTS OF THREE YEARS USE AT A SINGLE 
INSTITUTION. 
RCF Leonard 
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1Breast Unit, Western General, Edinburgh, 
2 South West Wales Cancer 
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Introduction: Although hormonal therapies are considered to be relatively 
well tolerated, there is audit evidence that medical professionals 
underestimate the distress caused by certain symptoms
1. Patients on chronic 
endocrine therapy may be given less time at clinics to discuss ￿minor￿ 
problems compared to patients receiving more toxic and complex cytotoxic 
regimens. Method: Over a 3 year period, breast cancer patients receiving 
endocrine therapy, attending the Edinburgh Breast Unit, were asked to 
complete a checklist of the symptoms they were experiencing (C-PET). This 
single page checklist took no more than two minutes to complete and was 
taken into the consultation to be used as a prompt for doctors and nurses, and 
to provide a better insight into side-effects experienced and how they were 
affecting the patient. Results: In the Edinburgh Unit 748 patients completed 
forms. Data on type of endocrine therapy and the symptoms experienced by 
each patient were examined. Most patients were on tamoxifen (524), 
anastrozole (103) and megestrol acetate (35). Data for these three therapies 
are reported. Other therapies included letrozole, formestane, goserelin and 
various combinations of these. The proportion of patients experiencing 
specific symptoms is shown in table 1. Tamoxifen symptoms were similar in 
the metastatic and adjuvant treatment patients so the data are aggregated, 
although perhaps unsurprisingly breathlessness and low energy were reported 
more frequently in the metastatic group. 
Table 1. Percentage of patients reporting symptoms 
HF SW WG NS FR SOB PVB PVD DR IR EN 
Tamoxifen 58  42  10  25  19 8 30  16  11  28 
Anastrazole 51  51 30 28  21 32  4  13 10  17  48 
Megestrol 
acetate 
40 43 57 11  40 49  14  11 11  20  49 
KEY: HF-hot flushes, SW-sweats, WG-weight gain, NS-nausea, FR-fluid 
retention, SOB-breathlessness, PVB-vaginal bleeding, PVD-vaginal 
discharge, DR-vaginal dryness, IR-irritability, EN-low energy. 
Other symptoms mentioned by patients included joint pain/stiffness 
(anastrozole), hair loss, dizziness and visual disturbance. 
Conclusion: This method was found to be a simple and speedy means of 
gaining information on symptoms associated with endocrine therapies, both 
in the clinic and as aggregated auditable data, and the data suggest that 
toxicity from endocrine therapies is more prevalent than previously reported 
1Leonard RC& Lee L 1996 The Breast (5) 259-264. 
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Minimal residual disease (MRD) detection is becoming an integral part of 
therapeutic protocols for childhood acute lymphoblastic leukaemia (ALL). 
Assessment for MRD at defined timepoints after diagnosis may allow risk 
stratification, prediction of relapse and the option of appropriately tailoring 
subsequent therapy. A number of protocols now utilise MRD results in the 
stratification of patients in clinical protocols. We have initiated a prospective 
study of MRD using both PCR based methodologies and multi-parameter 
flow cytometry in children entering into the MRC ALL97/99 (revised) trial. 
Samples (bone marrow) are collected from the patient at diagnosis and at 
days 8 and 28 during induction, at weeks 17 and 24 during intensification, at 
week 39 at the start of maintenance and thereafter at the end of treatment and 
at time of relapse if applicable. PCR protocols have been optimised to detect 
the five major translocations in childhood ALL: t(4;11) MLL-AF4; t(12;21) 
TEL-AML1; t(9;22) BCR-ABL p190 and p210; and t(1;19) E2A-PBX1. 
Sensitivity of detection ranges from 10
-2-10
-3 with standard PCR to 10
-4-10
-5
when using nested PCR with primers designed internally to the amplicon 
produced by standard PCR. At diagnosis, cells were examined by 
cytogenetics, flow cytometry and by routine qualitative RT-PCR for evidence 
of aberrant chromosome rearrangements or a leukaemia associated phenotype 
(LAP). Levels of MRD are monitored in translocation positive patients 
during treatment using real-time RT-PCR with 5’ nuclease (Taqman) probes 
in accordance with the Europe Against Cancer/Biomed group. Sensitivity of 
detection is 1 aberrant mRNA transcript within a population of 10
5-10
6 cells 
by PCR or . Patients who do not test positive for a chromosomal translocation 
are screened for clonal IgH, IgK, TCRδ  and TCRγ (B cell ALL) or TCRδ ,
TCRγ , SIL-TAL (T cell ALL). Following heteroduplex analysis, major clonal 
bands are sequenced and allelic-specific primers designed and utilised with 
consensus 5’ nuclease probes in real time PCR analysis. In parallel, the use of 
multiparameter flow cytometry to track MRD after initial therapy requires the 
detailed characterisation of an aberrant leukaemia associated phenotype 
(LAP) for each patient at diagnosis. Multiple combinations of antibodies 
from a panel of over 15 are used to test each diagnostic bone marrow sample 
for simultaneous expression of antigens. Patient-specific antibody 
combinations are then used in follow-up samples to quantitate MRD. A 
sensitivity to 10
-4 has been achieved with this technique.  To date, 30 patients 
have been enrolled in the study with a sampling range of 1-54 weeks. 
Minimal residual disease has been assessable to date in 23 patients using 
molecular and immunophenotypic analysis. MRD positivity has been 
detectable in 17/23 patients at Day 28 and in 14 patients MRD positivity has 
decreased over time. Evidence of MRD negativity has been detected in 5 
patients, but follow up time is short. Continued prospective monitoring of 
MRD in childhood ALL will help stratify patients for further therapeutic 
intervention.   Supported by the Childrens Leukemia Research Project. 
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Between 1972 and 1998, 101 consecutive adults over the age of 70 years 
were referred to the Department of Medical Oncology, for the management 
of ￿aggressive￿ NHL.  Data were available for 96 patients, (56 women) with 
the following histological subtypes (Kiel classification): centroblastic (36), 
high grade unclassified (25), immunoblastic (22), ￿other￿ (13).  All patients 
underwent routine staging with clinical examination, CT scanning, bone 
marrow biopsy and routine haematology and biochemistry investigations, 
resulting in: 28 patients with stage I disease, 22 stage II, 14 stage III and 31 
with stage IV disease.  The median age was 77 years (range 70-93).  88 
patients were treated with curative intent and 8 managed supportively.  66 
patients received combination chemotherapy according to protocols used at 
the time, and 22 were treated with radiotherapy (RT) with selection based on 
clinical findings.  No patients received growth factor support.    7 patients 
have been lost to follow up.    
Nine patients are alive, with a median follow up of 5 years (range 0.6 to 11.4 
years).  The actuarial proportion predicted alive at 5 and 10 years is 31 % and 
16%, respectively.  79 patients have died; 41 of lymphoma, 17 of treatment-
related causes, 5 of other malignancies, 7 of other known co-morbidity, and 
11 of unknown causes. 21 of 22 patients receiving RT completed planned 
therapy.  In contrast, only 7 of 66 (12%) patients receiving chemotherapy 
completed the intended treatment at full dose; 15 did not to due to treatment-
related death, 11 due to progressive disease, and 33 due to debility at 
diagnosis or resulting from treatment. Despite this, 22 patients (33%) 
achieved a complete response (CR) with an overall response rate of 62%. 
Early stage disease was a strong predictor of treatment response, with an 
overall response rate in stage I/II of 78% compared to that in stage III/IV of 
41% (p<0.001). Age examined as a continuous variable did not predict for 
response to treatment.  In the group that responded to treatment (CR and 
partial response) 5 year progression free survival (PFS) was 33%.   
Recurrence continued after 5 years, and at 10 years the PFS was 6%. 
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therapy for this patient population and confirm that it is possible to achieve 
long survival for a small proportion of elderly people with ￿aggressive￿ NHL.  
Advances in supportive care and the availability of additional but less toxic 
therapy may improve outcome. 
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THE SCHEDULE-DEPENDENT CYTOTOXICITY OF 
ETOPOSIDE IN LEUKAEMIC CELL LINES. 
WM Liu* and SP Joel. 
Dept Medical Oncology, St Bartholomew’s Hospital, London. 
Purpose: Etoposide is a commonly used anti-cancer agent that exerts its 
cytotoxic effects by stabilising transient topoisomerase II/DNA complexes 
that ultimately result in cell death. As part of our studies, the in vitro activity 
of etoposide (0-0.4 µ M) in a panel of leukaemic cell lines has been studied. 
Method: CEM and HL60 cells were cultured with etoposide following drug-
schedules of equal exposure duration (ED: duration x concentration), and cell 
parameters, including cell cycle distribution, were assessed daily. Results:
Proliferation assays showed etoposide to be an effective cytotoxic agent (IC50
on day 5 of 0.39 µ M and 0.15 µ M in CEM and HL60 respectively), showing 
concentration and duration-dependent activity. Flow cytometric analysis 
revealed etoposide to induce a block in the G2/M phase of the cell cycle 
which was transient, as continued exposure resulted in an emptying of cells 
from this phase (%G2/M in cells with 0.4 µ M on days 1, 3 and 5 was 62.1 – 
2.1%, 40.3 – 6.4% and 12.3 – 1.2% respectively, vs. 26 – 2.9% in control 
cells with no added etoposide). Importantly, this emptying was associated 
with an increase in apoptosis (%A in cells with 0.4 µ M on days 1, 3 and 5 
was 11.5 – 1.8%, 37.5 – 6.5% and 75.7 – 1.0% respectively). The 
comparison of a range of 8-day schedules with equi-ED consistently revealed 
a greater loss of percentage viability in cells cultured in schedules of longer 
duration of exposure. As an example, total % cell kill in CEM cells induced 
by a continuous exposure to 0.05 µ M etoposide was significantly greater than 
induced by either a 4-day exposure to 0.1 µ M or a single-day exposure to 0.4 
µ M etoposide. Furthermore, the total numbers of cells on day 8 were 
significantly smaller in schedules of longer duration (Table). 
8-day schedule (equi-ED = 0.4 µµµµ M.days) 
 0  x  8d  0.4  µµµµ M x 1d 
+ 0 x 7d 
0.1 µµµµ M x 4d 
+ 0 x 4d 
0.05 µµµµ M x 8d 
Total %CK*  12.3 ±  3.8%  42.3 ±  5.9%  125.2 ±  5.4%  193.4 ±  15.9% 
CC on day 8  46.4 ±  5.8  42.6 ±  4.7  13.6 ±  3.6**  4.2 ±  0.6*** 
CK = cell kill, CC = cell counts (x10
5 /ml). *p<0.001 when comparing CK in any two 
schedules. **p<0.001 vs. 0.4 µ M x 1d; ***p<0.001 vs. 0.1 µ M 4d. 
Conclusions: In addition to confirming the importance of total exposure to 
etoposide in determining cytotoxicity, we have also highlighted the 
importance of schedule in determining drug efficacy. Studies are continuing 
to elucidate the mechanisms of this schedule effect. 
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SUBSEQUENT PRIMARY CANCERS AFTER TREATMENT FOR 
HODGKIN￿S DISEASE AND NON-HODGKIN￿S LYMPHOMA  
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1 University of Sheffield, School of Medicine.  2.  YCR Academic Unit of 
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Background:  Numerous studies have shown that patients treated for 
Hodgkin￿s Disease or Non-Hodgkin￿s Lymphoma are at an increased risk of 
developing both leukaemia and solid cancers. 
Aims:  To determine the incidence of subsequent primary malignancies in 
patients treated for lymphoma at Weston Park Hospital, Sheffield. 
Methods:  A cohort of 3913 consecutive patients (2131 male, 1783 female), 
diagnosed with Hodgkin￿s Disease or Non-Hodgkin￿s Lymphoma before July 
2001, was identified using the Weston Park Hospital database.  Follow up 
was 95.2% complete for these patients. A search was undertaken for all 
patients diagnosed with a subsequent primary malignancy. Four patients who 
received treatment for their lymphoma at another centre and 13 patients in 
whom a second malignancy was diagnosed within six months of lymphoma 
diagnosis were excluded.  
Results: 63 new cancers in 60 patients were identified. The distribution of 
subsequent malignancies by lymphoma diagnosis and sex are expressed in 
the table below. 
Type of Subsequent Primary  HD Male HD female  NHL Male 
NHL 
Female Totals
Breast  Carcinoma  0  8 0 4  12 
Lung  Carcinoma  2  2 6 2  12 
Leukaemia or 
Myelodysplasia  4  2 2 0  8 
Colorectal Carcinoma  1  0  4  3  8 
Others  9  3 9 2  23 
Total 16  15  21  11  63 
At the close of the study, seven patients (11.67%) were alive, 52 patients 
(86.67%) had died and one (1.67%) had been lost to follow up. Registered 
cause of death included the subsequent malignancy in 49/52 patients 
(94.23%) Duration of follow-up ranged from six to 385 completed months 
(mean 115.8 months).    
Conclusions:  This study confirms a significant risk of subsequent primary 
malignancies in patients treated for lymphoma.  Actual relative risk and the 
relationship to different treatment modalities need to be evaluated in this 
population. 
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A RETROSPECTIVE STUDY OF PATIENTS WITH PAROTID 
LYMPHOMA AT THE PRINCESS MARGARET HOSPITAL, 
TORONTO. 
Rebecca Herbertson* 
Clinical Fellow in Haemato-oncology, St Bartholemew￿s Hospital, London
The aim of this study was to gain an understanding of the natural history of 
parotid lymphoma and how it has been treated over the last 30 years at The 
Princess Margaret Hospital in Toronto.  It was intended to identify patient 
and tumour characteristics, treatment received and trends in response and 
outcome.  47 patients were identified as having biopsy proven primary 
parotid lymphoma between 1967 and 1998.  Data was collected from the 
hospital database, the patient notes and the hospital computerised records.  
The endpoints evaluated were disease free survival and overall survival.  The 
median age at diagnosis was 63yrs.  Nine patients had documented bilateral 
disease (6 of these had MALT lymphoma) and three patients (6.4%) had B-
symptoms at presentation.  The Karnofsky performance status ranged from 
30-100%, the median being 90%.  Fourteen patients had high-grade 
lymphoma (12 of these were diffuse large cell) and 33 had low-grade disease 
(13 of these were MALT lymphoma).  The majority of patients presented 
with an asymptomatic lump (91.5%).  At diagnosis 43 patients had stage 1 
and 2 disease, and 4 patients had stage3 and 4 disease.  Only 3 patients 
reported B symptoms and 19 patients had a tumour bulk of greater that 5 cms. 
Of the 13 patients with MALT lymphoma 5 patients were known to have a 
pre-existing diagnosis of Sjogrens disease. Three patients received bilateral, 
and ten patients received unilateral radiotherapy alone.  Two received 
chemotherapy alone, and 2 received surgery alone. Fourteen patients received 
surgery followed by radiotherapy to the effected parotid gland.  Two patients 
received surgery followed by bilateral parotid radiotherapy.  Five patients had 
initial surgery, unilateral radiotherapy and then systemic chemotherapy.  A 
further 7 patients studied underwent unilateral radiotherapy followed by 
chemotherapy.  Following first line therapy, thirty-six patients achieved a 
complete remission.  Two patients had progressive disease despite treatment 
and one demonstrated a partial remission.  Seventeen out of 47 patients were 
later documented to have relapsed and five of these had evidence of more 
than one relapse.  Of those who relapsed 2 patients had follicular mixed cell, 
4 had follicular large cell, 4 had small cell, 4 had diffuse large cell, 1 had 
diffuse mixed and 2 had MALT lymphoma.  Disease free survival and overall 
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patients with diffuse large cell and T cell lymphoma had the shortest DFS and 
OS (33(mean) and 50 months respectively), and those with follicular mixed 
cell lymphoma had the longest mean DFS and OS (99 and 152 months 
respectively).  This study looked at a sample of patients with different types 
of primary lymphoma of the parotid gland and demonstrated that in general it 
is a localised disease with an indolent course.  The treatment received and 
subsequent outcome of disease was dependent on the histological type and 
stage at diagnosis.  Because MALT lymphoma was recognised as a disease 
entity in 1994, the number of patients diagnosed with this (and their long-
term outcome) is likely to have been underestimated in this sample.  A 
further study to review all the histological diagnoses on this group of patients 
is planned for the future.  
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THE SYSTEMIC INFLAMMATORY RESPONSE PREDICTS BOTH 
CANCER SPECIFIC AND NON-CANCER SURVIVAL IN PATIENTS 
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Background: The assessment of prognosis in patients with advanced 
lymphoma is problematical. The value of C-reactive protein concentration in 
this context has not been clearly defined. 
Methods: Patients with a diagnosis of lymphoma (Hodgkins n=114 and non-
Hodgkins lymphoma n=40) and who had measurements of C-reactive protein 
and albumin were studied. Results: Median survival, from the time of 
sampling was 241 days. On univariate analysis there was a significant 
relationship between C-reactive protein, albumin concentrations and the 
duration of cancer specific survival (p<0.0001). In contrast, tumour type 
(p<0.05) and C-reactive protein (p<0.0001) were related to the duration of 
non-cancer survival. The hazard ratio associated with a unit increase in log10
C-reactive protein concentration (i.e. a tenfold increase in C-reactive protein 
concentration) was 74.01 (95% CI 30.07- 182.16) and 4.622 (95% CI 2.325- 
9.190) for cancer specific and non-cancer survival respectively. 
Conclusions: The results of the present study demonstrate that patients with 
advanced lymphoma have evidence of a systemic inflammatory response and 
the magnitude of that response strongly predicts the duration of cancer 
specific and non-cancer survival. 
Keywords; C-reactive protein, albumin, lymphoma, cancer specific survival. 
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CYTOKERATIN 19 IMMUNOHISTOCHEMISTRY AND 
ASSESSMENT OF DEPTH OF MYOMETRIAL INVASION IN 
STAGE I ENDOMETRIAL CANCER
Alexander-Sefre F, Singh N, Jacobs I.,  Gynaecological Cancer Research 
Unit, St Bartholomew￿s Hospital, London 
Introduction:  
Approximately 50% of endometrial cancer (EC) deaths occur in patients with 
stage I disease at presentation. Depth of myometrial invasion is the most 
important risk factor for lymph node metastasis and mortality. Assessment of 
depth of invasion is currently done by light microscopic examination of   
H&E stained sections.  
Tumour cells can evade detection by light microscopy if they are isolated and 
vastly outnumbered by myometrial and inflammatory cells. In non-
gynaecological cancers, immunohistochemical staining of tumour cells has 
proven value in detecting isolated infiltrating cells and lymphovascular 
invasion (LVI), which correlate well with tumour recurrence. 
Cytokeratin 19 belongs to a family of 20 related polypeptides that are 
constituents of the intermediate filaments of epithelial cells. This protein is 
expressed in normal and neoplastic endometrial epithelial cells.  
Objective:  
To investigate the role of CK-19 immunohistochemistry (IHC) in assessing 
myometrial invasion in stage I EC and to determine its clinical importance.  
Methods: 
A total of 111 stage I EC patients with minimum 4 years  follow-up were 
selected. Representative H&E stained sections were re-examined by a 
pathologist to identify blocks containing tumour with maximum myometrial 
invasion. Four micron sections from the selected blocks were stained for CK-
19 using a standard avidin-biotin method. The immunostained sections were 
then examined by the same pathologist and the results compared with H&E 
findings. Cases suspected to have LVI were dually stained with CD-31 and 
Pancytokeratin to confirm true LVI. 
Results: 
Endometrial tumour cells showed positive though variable immunoreactivity 
for CK-19.  Immunohistochemical assessment revealed deeper myometrial 
invasion than detected on H&E staining in seven cases (6 %). Thirty four 
cases were noted to have LVI that was not detected on H&E sections. CD-31 
staining confirmed true LVI in 29 cases (26%). 
Conclusions: 
CK-19 IHC can detect isolated infiltrating tumour cells. It therefore has 
potential advantage over routine histology in accurate assessment of 
myometrial invasion in stage I EC. CK-19 IHC identifies lymphovascular 
invasion with much greater sensitivity than H&E staining by CK-19 IHC. 
We aim to correlate the presence of isolated infiltrating cells and LVI 
identified solely by CK-19 IHC with known adverse clinico-pathological 
features, disease recurrence and overall survival. 
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Background: Thalidomide is anti-angiogenic and has activity as a single 
agent against several tumour types. The mechanism of action of thalidomide 
has not been well characterised and its safety in combination with 
chemotherapy not assessed.   
Methods: Patients receiving carboplatin (AUC 7) every 4 weeks for stage Ic 
￿ IV ovarian cancer were randomised to 6 months of thalidomide 100mg 
daily or no additional treatment. Surrogate markers of angiogenesis, 
including vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF), von Willebrands factor (vWF), vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin were measured before treatment and 
after each cycle of chemotherapy. Patients randomised to thalidomide had 
sensory nerve action potentials (SNAP) performed every 2 months.   
Results: 34 patients (Median age 64 years, range 41 - 88 years) have been 
recruited  (16 carboplatin, 18 carboplatin and thalidomide) and 26 are 
evaluable to date. There were no significant differences in response rates or 
toxicity between the groups. No patients on thalidomide had a significant fall 
in SNAP. Preliminary analysis (n=21) showed elevated baseline serum 
VCAM-1 and urinary VEGF in patients with more than 2cm residual disease 
post-operatively compared to those with less than 2cm.  There was a 
significant decrease (paired T-test, p < 0.05,) in E-selectin and VCAM-1 on 
paired samples, between baseline and end of treatment for all patients 
analysed together. There were no significant differences between the two 
patient groups for any of the markers analysed.  
Conclusions: Low dose oral thalidomide can be safely administered in 
combination with carboplatin chemotherapy. Potential surrogate markers of 
angiogenesis fall in response to both carboplatin alone and carboplatin plus 
thalidomide.  
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COX-1 AND COX-2 EXPRESSION IN INVASIVE CERVICAL 
CANCER: RELATIONSHIP TO PROGNOSIS AND 
CLINICOPATHOLOGICAL FACTORS
Athavale RD**, Clooney K
#, O￿Hagan J*, Shawki H
#, Clark AH
#, Green JA*
**Liverpool Women￿s Hospital *University of Liverpool 
#Arrowe Park 
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BACKGROUND: COX-1 and COX-2 are members of the cyclooxygenase 
enzyme family, which may have a role in tumour invasion and influence 
apoptosis. COX-2 was significantly overexpressed in women treated 
surgically for early stage cervical carcinoma (FIGO stage IB) with lymph 
node or parametrial involvement (Ryu et al . Gynecol Oncol 2000;76:320-
25). COX-2 expression has also been linked with reduced cause-specific 
survival and pelvic control in women treated with radiotherapy (Gaffney et 
al. Am J Clin Oncol 2001 Oct;24(5):443-6).  The purpose of our study was to 
assess the role of COX-1 and COX-2 expression in the prediction of survival 
in early stage cervical carcinoma and to examine the relationship between the 
expression and clinicopathological factors. PATIENTS AND METHODS:
Women diagnosed to have early stage cervical carcinoma and treated at the 
same cancer centre between 1981 and 1990 and for whom tissue blocks were 
available were included in this study. The median followup interval was 157 
months (60-212 months). 27/28 women had squamous cell carcinoma and 
one had cervical adenocarcinoma. 23/28 tumours were moderate to poorly 
differentiated and 2/28 were well differentiated. The treatment was with 
surgery alone (n=17), radiotherapy alone (n=3), surgery and radiotherapy 
(n=3) and surgery with radiotherapy and subsequent chemotherapy (n=5). 
COX-1 and COX-2 expression were assessed by immunohistochemistry 
(IHC) by the same pathologist (AC) who was blinded to the survival 
outcomes. A four point score (0-4% or negative = 0, 5-24%=1, 25-49%=2, 
50-74%=3 and 75-100%=4) was allocated for distribution and intensity was 
recorded on a 3 point score. Survival curves were plotted for distribution 
alone and using a combined score of distribution and intensity (0-3=low, 4-
7=high). Prognostic factors examined included histological grade, tumour 
size at initial surgery and lymph node spread of tumour. The data was 
analyzed with SPSS release 10.0. RESULTS: COX-1and COX-2 were 
expressed in 61%(17/28) and 57% (16/28) of tumours respectively.  7 out of 
8 women who died (between 4-33 months) overexpressed COX-1 (p=0.04) 
and 5 out of 8 expressed COX-2. Women with a weak expression of COX-2 
(5-24%) and those with a low combined score for COX-1 showed a trend 
towards an improved survival as compared to strong expressers and high 
combined scores respectively. Moderate to poorly differentiated tumours 
appeared to overexpress both COX-1 (16/23 versus 17/28 overall) and COX-
2 (15/23 versus 16/28 overall). There was no significant difference between 
tumour size and COX-1 or COX-2 expression. 2 out of 3 women with lymph 
node spread expressed both COX-1 and COX-2. CONCLUSION: This study 
suggests that increased expression of COX-1 and COX-2 may be associated 
with a poorer survival prognosis. A prospective evaluation of the 
cyclooxygenase enzymes particularly COX-2 may prove to be useful in 
selecting women with early stage cervical cancer for chemoradiotherapy. 
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The aim of this study was to assess the interrelationships between growth 
regulatory genes, human papillomavirus (HPV) and grade of CIN.  The 
frequency of HPV-DNA in this retrospective series of 200 cases was 72% of 
cases assessed by a sequential combination of NISH and PCR based analysis.  
A strong statistical association between the presence of ￿high risk￿ oncogenic 
HPV types (16/18 and 31/33/51) and the development of CIN2 or 3 was 
observed (X
2=12.49:p<0.0005).  Similarly, the ￿low risk￿ non-oncogenic 
HPV types (6/11) were associated with the development of low-grade CIN 
lesions (CIN1 or wart virus).  This data supports the hypothesis that the 
transforming capacity of HPV is subtype specific.  The expression of p53 was 
reduced in oncogenic HPV type tissues as compared to non-oncogenic sub-
types (
2=30.8 :P<=0.0003), and was also less in higher grade CIN lesions as 
compared to CIN1 (
2=5.5: p<0.02).  This loss of expression supports the 
hypothesis that p53 is functionally inactivated by complex formation with the 
E6 and E7 oncoproteins of ￿high risk￿ HPV types.  A similar association was 
found between loss of RB expression and increasing grade of CIN (
2=16.9: 
p<0.0001).  An increased level of p53 was observed in the parabasal layer of 
dysplastic lesions with non-oncogenic HPV sub-types and deemed to be 
persistent wild type gene products.  EGFr expression was found to be reduced 
in expression with decreased p53 expression (
2=6.07:p=0.014), but there 
was no relation to the other variables. 
These results suggest that the presence of oncogenic HPV types and the loss 
of p53 and pRB expression may be prognostic indicators in CIN, and may 
complement histopathological assessment of the malignant potential of 
dysplastic lesions. 
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Introduction: Granulosa cell and Sertoli-Leydig cell tumours account for 5-
6%of all malignant ovarian cancers. Previous studies have shown that the 
majority of tumours are FIGO stage 1 at presentation and are associated with 
a 70-90% 5 year survival rate. The aim of this study was to look at the current 
patterns of presentation, treatment and outcome of these tumours. 
Methods: A 10 year retrospective notes review. Information was abstracted 
on patient characteristics, disease presentation and stage, treatment and 
outcome, including relapse and death. Histology reports were reviewed by a 
pathologist.  
Results: A total of 15 granulosa cell tumours were recorded, with a mean age 
of 62.1 years (range 44-83 years) and documented stages Ia:n=1, Ib:n=2, 
Ic:n=5, II:n=2, III:n=4, unknown in 1 case. Surgery composed of TAH BSO 
in 11 cases, and the median tumour size was 12cm (2.5-23cm). Washings 
were positive in 6 cases. Additional treatment was pelvic radiotherapy in one 
case. Six patients received platinum based chemotherapy, of whom 3 have 
recurred at 8, 17 and 72 months. One patient had died at 12 years and 12 are 
alive at a median of 5 years. Eight Sertoli-Leydig tumours were seen, with a 
mean age of 47 years (range 17-63 years), and recorded stages I:n=2, II:n=2, 
III:n=2 and 1 stage IV, unknown in 1 case. Size ranged from 5.5-19cm. Five 
tumours ruptured at resection. TAH BSO was carried out in only 3 cases and 
unilateral oophorectomy in 5 cases. Six patients received platinum based 
chemotherapy, of whom 5 responded, but 4 have relapsed at 6-19months. 
Three patients are alive at 8-48 months, the remainder are dead at 6-30 
months. 
Histology reports were available on 18 patients and these showed a great 
variation in the extent and content of both the macroscopic and microscopic 
descriptions. Information which may have prognostic significance, including 
capsule penetration, appearance of the nuclei and mitotic counts, was often 
not recorded. Only 4 of the 18 cases were referred for an external expert 
opinion. 
Conclusions: This study highlights the inconsistency in the diagnosis, 
management and treatment of women with granulosa cell or Sertoli-Leydig 
cell ovarian tumours. This study is now being extended to cover the 
Merseyside and Cheshire area, a population of over 2 million people, from 
1980-2000, and will include an audit of the pathology reporting. 
Significant improvement in the management of rare cases will only be 
obtained by studies with large patient numbers, which will only be possible 
through international collaboration.  A central tumour registry with co-
ordinated data collection and prospective clinical trials is proposed.  
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